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Abstract
Background: The current treatment paradigm for type 2 diabetes mellitus (T2D) typically involves use of multiple
medications to lower glucose levels in hope of reducing long-term complications. However, such treatment does
not necessarily address the underlying pathophysiology of the disease and very few patients achieve partial,
complete, or prolonged remission of T2D after diagnosis. The therapeutic potential of nutrition has been highlighted
recently based on results of clinical trials reporting remission of T2D with targeted dietary approaches. During the initial
phase of such interventions that restrict carbohydrates and/or induce rapid weight loss, hypoglycemia presents a
notable risk to patients. We therefore hypothesized that delivering very low-carbohydrate, low-calorie therapeutic
nutrition through community pharmacies would be an innovative strategy to facilitate lowering of glycated
hemoglobin (A1C) while safely reducing the use of glucose-lowering medications in T2D.
Methods: A community-based randomized controlled trial that is pragmatic in nature, following a parallel-
group design will be conducted (N = 200). Participants will have an equal chance of being randomized to
either a pharmacist-led, therapeutic carbohydrate restricted (Pharm-TCR) diet or guideline-based treatment as
usual (TAU). Pharm-TCR involves a 12-week very low carbohydrate, calorie-restricted commercial diet plan led
by pharmacists and lifestyle coaches with pharmacists responsible for managing medications in collaboration
with the participants’ family physicians. Main inclusion criteria are diagnosis of T2D, currently treated with
glucose-lowering medications, age 30–75 years, and body mass index ≥ 30. The primary outcome is a binary
measure of use of glucose-lowering medication. Secondary outcomes include A1C, anthropometrics and
clinical blood markers.
Discussion: There are inherent risks involved if patients with T2D who take glucose-lowering medications follow very
low carbohydrate diets. This randomized controlled trial aims to determine whether engaging community pharmacists
is a safe and effective way to deliver therapeutic carbohydrate restriction and reduce/eliminate the need for glucose-
lowering medications in people with T2D.
Trial registration: ClinicalTrials.gov, NCT03181165. Registered on 8 June 2017.
Keywords: Diabetes, Ketogenic diet, Glucose, A1C, Diet, Nutrition, Pharmacy, Insulin
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: jonathan.little@ubc.ca
1School of Health and Exercise Sciences, University of British Columbia,
Kelowna, BC V1V 1V7, Canada
Full list of author information is available at the end of the article
Durrer et al. Trials          (2019) 20:781 
https://doi.org/10.1186/s13063-019-3873-7
Background
Diabetes mellitus affects ~ 10% of the Canadian population,
with worldwide estimates that 628 million will have diabetes
mellitus by 2045 [1]. Approximately 90% of all cases are type
2 diabetes mellitus (T2D) [1]. T2D contributes to a signifi-
cant increase in morbidity and mortality due to numerous
complications attributed to hyperglycemia, hyperinsulinemia,
insulin resistance, and associated metabolic dysfunction [2].
The current treatment paradigm for T2D typically involves
use of multiple medications to lower glucose levels in hopes
of reducing long-term complications [3]. Specifically, if pa-
tients with T2D fail to lower hemoglobin A1C (A1C)
through lifestyle modification within 3 months, they are
started on a treatment regimen beginning with metformin
and progressing with the addition of other antihyperglycemic
agents until A1C targets are achieved. These antihyperglyce-
mic agents operate through a variety of mechanisms to lower
blood glucose; however, the mortality benefits of different
add-on medications appear to be different [4–7]. However,
this treatment does not necessarily fix the underlying patho-
physiology of the disease and studies indicate that T2D is
typically a chronic, progressive disease with only < 2% of pa-
tients achieving partial, complete, or prolonged remission of
diabetes mellitus after diagnosis [8]. When patients are taking
multiple medications, the treatment plan requires involve-
ment and integration of care from not only physicians but
also pharmacists. Indeed, it has been demonstrated
that patients with T2D have more annual visits to
their pharmacist than their primary care physician,
placing the pharmacist in a key position for overall
management of diabetes mellitus [9].
Lifestyle interventions including diet and exercise are
often stated as frontline treatments for T2D, either alone
or in combination with medications [10, 11]. In particu-
lar, the therapeutic potential of nutritional interventions
has been highlighted recently based on results of clinical
trials reporting “remission” of T2D with targeted dietary
approaches [12, 13]. In a non-randomized trial, a remote
continuous care model delivering a very low carbohy-
drate, high fat, non-calorie-restricted diet was effective
at lowering A1C, promoting weight loss, and reducing
the use of glucose-lowering medications (including insu-
lin) in patients with T2D [14, 15]. The authors reported
T2D “reversal” (defined in this study as A1C below dia-
betes mellitus thresholds and taking no glucose-lowering
medications except for metformin) at both 10 weeks [15]
and 1 year [14]. In a cluster randomized controlled trial
(RCT) involving primary care practices, Lean et al. [12]
showed that a calorie-restricted (~ 850 kcal day) total
diet replacement method followed by food reintroduc-
tion at 12 weeks was effective at inducing remission of
T2D (defined as non-diabetic A1C and taking no
glucose-lowering medications) in 46% of patients at 1
year. Remission of T2D in this trial was tied to not only
weight loss [12] but also rescue of beta-cell function
[16]. It is currently unclear whether a very low carbohy-
drate (< 50 g/day) diet [17] or a more prescriptive low-
calorie approach [12] is superior for T2D remission/re-
versal and we are unaware of any trials specifically com-
paring these two therapeutic nutrition options. However,
it stands to reason that a combined approach incorpor-
ating a diet that is both very low carbohydrate and low
calorie may be the most potent for lowering blood glu-
cose, promoting weight loss, and achieving T2D reversal.
During the initial phase of therapeutic nutrition inter-
ventions that restrict carbohydrates and/or induce rapid
weight loss, hypoglycemia presents a notable risk to pa-
tients [18, 19]. Indeed, it has been demonstrated that,
even prior to weight loss, low carbohydrate diets result
in lower glycemia in people with T2D [20]. While rarely
addressed in depth, careful medication management and
reduction during this period are essential to prevent
hypoglycemia and minimize risk [21, 22]. Pharmacists
are well-positioned for this role and are educated in
medication management and T2D. Studies exploring in-
tegrative care wherein pharmacists play an active role in
T2D management have demonstrated positive impacts
on T2D outcomes [23]. We therefore hypothesized that
the innovative strategy of delivering very low carbohy-
drate, low-calorie therapeutic nutrition through commu-
nity pharmacies would facilitate lowering of A1C while
safely reducing the use of glucose-lowering medications
in T2D, particularly in more complex cases in which in-
dividuals are taking multiple medications or insulin. To
this end, we designed an RCT to determine if commu-
nity pharmacist-led therapeutic carbohydrate restriction
could eliminate glucose-lowering medications and facili-
tate T2D reversal/remission.
Study objectives
The study objectives are:
1. To determine if people with T2D are able to reduce
and/or eliminate their need for glucose lowering
medications by utilizing a pharmacist-led, thera-
peutic carbohydrate restricted (Pharm-TCR) diet.
2. To determine if following the Pharm-TCR diet will
lead to improvements in body composition, blood
glucose control, and cardiometabolic health in
people with T2D.
3. To determine if following the Pharm-TCR diet will
lead to improvements in quality of life in people
with T2D
Data will also be collected for possible future health
economics analysis (e.g., medication costs). Trial results
will be published.
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Methods/design
A community-based randomized controlled trial that is
pragmatic in nature, following a parallel-group design
will be conducted. Patients with T2D (N = 200) will be
recruited from across 12 pharmacy locations in the prov-
ince of British Columbia, Canada. The pharmacists will
use a secure password-protected website maintained by
the University of British Columbia (UBC) Centre for
Health Evaluation and Outcome Sciences (CHEOS) to
implement the random allocation sequence. The secure
website provides allocation concealment until the
interventions are assigned. The allocation sequence gen-
erated was by a researcher from CHEOS using PROC
PLAN in SAS 6.4 software. Participants will be stratified
by site (pharmacy) and glucose-lowering medications
(two or fewer, three or more (or taking exogenous insu-
lin)) and randomized in a 1:1 allocation ratio using per-
muted block sizes, to either the therapeutic nutrition
group or the treatment-as-usual (TAU) group. Due to
the nature of the interventions and the involvement re-
quired of the pharmacists, they cannot be blinded to
final treatment allocations of the participants. The
protocol was approved by the University of British
Columbia Clinical Research Ethics Board (H16–01539)
and the trial was registered on ClinicalTrials.gov
(NCT03181165) on 8 June 2017. A flow diagram of the
trial is presented in Fig. 1. Additional file 3 contains the
SPIRIT 2013 Checklist.
Primary outcome
The primary outcome is the proportion of patients with
T2D who are either using or no longer using glucose-
lowering medications after the 12-week study period.
Secondary outcomes
The secondary outcomes are:
 Hemoglobin A1C (%)
 Percentage dose reduction in glucose-lowering medi-
cations (change in daily dose)
 Body mass index (BMI) (kilograms/meters squared)
and weight reduction (kilograms)
 Waist circumference (centimeters)
 Body fat percentage (%)
 Health-related quality of life (SF-20)
 Blood lipid profile (total, high-density lipoprotein
(HDL) and low-density lipoprotein (LDL) choles-
terol, triglycerides), liver function tests (alanine ami-
notransferase (ALT), aspartate aminotransferase
(AST), gamma-glutamyl transpeptidase (GGT)), fast-
ing plasma glucose, pro-insulin, insulin, and C-
peptide
Fig. 1 Trial Flow Diagram
Pharm-TCR, Pharmacist-led, therapeutic carbohydrate restricted diet; TAU, Treatment-as-usual
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 Blood pressure (millimeters of mercury)
 Percentage dose reduction in blood pressure-
lowering medications (change in daily dose)
Participant recruitment
We aim to recruit 200 participants (equal probability of
randomization to each arm) using a combination of
newspaper advertising, online advertising, recruitment
posters posted in pharmacies, and by word of mouth in
each respective study site location. Potential participants
who respond to the recruitment material will be directed
to the nearest study site and invited to attend a screen-
ing appointment where the study will be fully explained
and discussed. Participants will provide written informed
consent and their primary care physician will be in-
formed of their participation prior to any data collection.
The pharmacists at each site will obtain consent.
Inclusion criteria
The inclusion criteria are:
 Written informed consent
 Men and women aged 30–75 years
 Diagnosed with T2D by a physician
 Using at least one glucose-lowering medication
 BMI ≥ 30 kg·m2
Exclusion criteria
The exclusion criteria are:
 History of heart attack or coronary artery disease
within the previous 2 years
 Any current unstable cardiovascular disorder
 History of liver disease
 History of kidney disease or impaired renal function
 Currently pregnant or lactating, or planning on
becoming pregnant within the next 12 months
 Any diagnosed neurological disorder
 History of bariatric surgery
 History of cancer within the previous 5 years
 Dietary restrictions that would inhibit adherence to
the intervention diet
Trial procedures
Eligible participants who enroll in the study will undergo
baseline assessment of medications and A1C, fasting glu-
cose, triglycerides, liver ALT, AST, GGT, serum triglycer-
ides, HDL and LDL cholesterol, and high sensitivity (hs)-
C-reactive protein (hs-CRP). Weight, height, BMI, body
fat percentage (measured by bioelectrical impedance), and
waist circumference will be taken as anthropometric mea-
surements, and quality of life will be assessed using the
SF-20 questionnaire. Participants’ primary care physicians
will be notified of all laboratory results as per typical blood
requisition (by fax). Participants will fill out a 3-day diet
record to assess habitual food intake and the Godin
Leisure-Time Exercise Questionnaire to assess typical
physical activity. Participants will also be asked to fill out a
questionnaire regarding their ethnicity and socioeconomic
status. Following the baseline assessments, participants are
randomized to either the Pharm-TCR diet group or the
TAU control group. A simplified cost-effectiveness ana-
lysis including the cost of medications and cost of the
foods and pharmacists’ time during the intervention will
be conducted as an exploratory outcome.
Pharm-TCR intervention (0–12 weeks)
Participants randomized to the Pharm-TCR group will meet
with a pharmacist and a lifestyle coach at a community phar-
macy. The pharmacist will review all medications with the
participant and then develop a care plan, including medica-
tion recommendations (Additional file 1), to be shared and
approved by the participant’s physician (by fax, using existing
standard procedures for any medication adjustments recom-
mended by pharmacists). Any adjustments to care made by
the physician will be incorporated into the plan. The lifestyle
coach or pharmacist will then educate the participant on the
components of the intervention and review the Pharm-TCR
food options, which are standardized by using a combination
of whole foods and supplemental foods from a commercial
weight loss diet (Ideal Protein). This commercial diet plan
(provided to the participants free of charge) provides a var-
iety of low-carbohydrate, energy-restricted, adequate-protein
meals and snacks that are used in combination with a
selected group of meats and a wide range of vegetables in
order to create a personalized meal plan for each participant.
Participants will not otherwise be remunerated for participat-
ing in the trial. The macronutrient composition of the meal
plan equates to < 50 g of carbohydrates, ~ 35-45 g of fat, and
~ 110-120 g of protein for a total of approximately 850–
1100 kcal per day. Pre-packaged foods are used for two meals
and one snack each day, with the third meal being prepared
from a select group of lower-fat protein sources (e.g., meat,
eggs) and low-carbohydrate vegetables. The use of a com-
mercial weight loss diet plan allows for tight control over the
amount of carbohydrates consumed and the overall energy
intake. This approach was chosen because the consistency
makes medication adjustments more predictable and repro-
ducible for the pharmacist. This is essential as the pharma-
cists will need to manage medication adjustments in
anticipation of, and in response to, the rapid glucose-
lowering effects of this specific low-carbohydrate low-calorie
dietary intervention, even prior to substantial weight loss. For
patients who are taking > 30 units of exogenous insulin per
day at the start of the study, a modified TCR meal plan is
used, which includes 80–100 g of carbohydrates per day. This
is to reduce potential risk of hypoglycemia during the insulin
de-escalation phase of the study (details below and in
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Additional file 1). Once a participant’s insulin dose is < 30
units per day they are transitioned to the regular TCR meal
plan incorporating < 50 g of carbohydrate per day with
remaining insulin dose being reduced by a further 50% on
day 1.
Following the initial visit, participants will be required
to report to the pharmacy each week to meet with the
lifestyle coach and pharmacist in order to monitor pro-
gress, collect intervention foods, and receive counseling
on dietary adherence for the week ahead (total of 12
visits). At this time, the pharmacist will review the
current status of the care plan with the patient, make ad-
justments as necessary, and communicate as appropriate
with their physician. The care plan is individualized to
each participant based on their baseline medication
usage and blood glucose measurements using a
standardized medication deprescribing framework as
outlined in Additional file 1. Participants’ medication
usage, weight, height, waist circumference, body fat per-
centage, blood pressure, and capillary ketone levels are
also recorded during these visits and a 3-day diet record
is filled out again on week 6. On the final visit, partici-
pants are assessed for the same blood, anthropometric,
quality of life, and habitual physical activity measures
that were collected at baseline.
Treatment-as-usual control (0–12 weeks)
Participants randomized to the TAU group will
undergo a medication review by the pharmacist, will
be provided with standard medication advice by their
pharmacist, and will be given information pamphlets
on diet and lifestyle conforming with 2013 Diabetes
Canada (formerly the Canadian Diabetes Association)
Clinical Practice Guidelines. This information is evi-
dence based and recommends participants to follow a
low-fat, low glycemic-index diet and to engage in 150
min of moderate activity per week. Standard clinical
practice recommends an A1C test and potential medi-
cation adjustments every 3 months (typically an
increase in dose or number of glucose-lowering drugs
if A1C does not reach below the clinical target of
< 7.0%) and therefore the treatment period of 12
weeks was chosen.
Three-day food records will be collected at baseline,
week 6, and week 12 to assess the energy and macronu-
trient content of the foods consumed. Following week
12, TAU participants will return to the pharmacy for a
final visit where they are assessed again for all baseline
blood, anthropometric, quality of life, and habitual phys-
ical activity measures.
In order to help retain TAU-group participants for
follow-up testing they will be offered participation in the
Pharm-TCR intervention after the TAU period has
completed. If a TAU-group participant chooses to try
the dietary intervention following completion of the
TAU period, the participant is considered to have fin-
ished the trial and as such, no study data will be col-
lected from them during this time period.
Patient safety
During the first 2–4 weeks of the program (when most
medication adjustments are made), participants commu-
nicate frequently with their pharmacist and lifestyle
coach via phone call and/or text messaging and take fin-
ger stick blood glucose measurements four times per
day (a fasting measurement upon waking, and before
lunch, dinner, and bedtime). This allows for feedback
and assessment of the medication reductions and helps
to reduce any potential risk of hypoglycemia. Partici-
pants are instructed on steps to take if blood glucose is
< 3.9 mM and/or they have symptoms of hypoglycemia;
the steps include consumption of an energy bar contain-
ing 15 g of carbohydrates and, if severe or if symptoms
do not resolve, reporting to their doctor or emergency
room. All observations/results that may pose a risk to
health will be discussed with the study team and all
adverse events will be recorded. Pharmacists at each site
will be closely engaged with participants due to the
nature of the intervention. Any safety concerns will be
brought to the attention of the study physician, Dr. Jay
Wortman and the lead pharmacist (Mr. Sean McKelvey).
A safety committee of two independent physicians with
experience in low-carbohydrate diets and T2D will re-
view any adverse events and provide clinical insight into
their etiology. These two independent physicians can re-
quest stoppage or changes to the ongoing study. The
Principal Investigator (PI) (Dr. J. Little) will meet with
Dr Wortman, Mr. McKelvey, and the two independent
physicians every 6 months or as often as needed, to re-
view any safety issues or data collection issues. If there
are any serious adverse events, the independent physi-
cians or study physician can recommend that any/all
participants discontinue participation in the trial. Partici-
pants may also choose to discontinue at any time. Phar-
macists at each site will have access to the data as they
are collected. They will fax or email any data, with no
personal identifiers, to the PI or study email address at
the UBC. Only study investigators will have access to the
faxed or emailed data. Any personally identifying data
collected by the pharmacists will be de-identified prior
to being sent to the research team.
Protocol delivery fidelity
A standard training protocol has been developed to
minimize variability and maintain the intervention
protocol across all pharmacies. Training videos followed
by visits in person by the study coordinator will be used
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to explain the study design, aims, and protocol to the
study personnel at each pharmacy. The study coordin-
ator will remain easily accessible to the pharmacy
personnel via email and phone throughout the study.
The head study pharmacist teaches the medication ad-
justment framework to the lead pharmacist from each
study site, by in-person workshops that include both a
lecture portion and multiple case studies. The head
study pharmacist will also be available to the site phar-
macists via email and phone throughout the study.
Measurements
The measurements taken at each stage of the study are
detailed in the Additional file 2. Height will be measured
to the nearest millimeter, using a stadiometer (Seca,
model 700, Germany). Body weight will be measured to
the nearest 100 g (Tanita, model DC-430 U, IL, USA)
with the participant wearing light clothing without
shoes. Waist circumference is assessed by measuring the
distance around the waist at the top of the iliac crest.
Blood pressure will be measured using the PharmaSmart
Model PS-2000C (BC, Canada) after the participant has
been seated, at rest, with legs uncrossed for at least 5
minutes. Body fat percentage will be assessed by bioelec-
trical impedance analysis (Tanita, model DC-430 U, IL,
USA). Briefly, participants stand on the scale with soles
and heels of both of their feet in contact with the elec-
trodes and the participants’ sex, height, and weight are
used in combination with the measured resistance to
calculate body fat percentage. Tanita has validated this
method in people with T2D against dual x-ray absorpti-
ometry (r = 0.89, p < 0.0001) [24].
Participants in the Pharm-TCR group will have their
capillary ketone levels measured at each weekly visit
using a Freestyle Precision Neo device (Abbott Labora-
tories, CHI, IL, USA). Clinical laboratory requisitions
will be given to the participants for blood to be collected
at a local clinical laboratory (LifeLabs or Valley Medical
Labs) at baseline and post Pharm-TCR intervention or
TAU control, to measure A1C, fasting glucose, triglycer-
ides, ALT, AST, GGT, serum triglycerides, HDL and
LDL cholesterol, and hs-CRP. A subsample of partici-
pants will have fasting C-peptide, insulin, and proinsulin
measured to estimate homeostasis model assessment of
insulin resistance (HOMA-IR) and beta-cell function
based on HOMA-B and C-peptide–proinsulin ratio. This
subsample analysis of the plasma samples collected by
the clinical laboratory will be performed by the research
team at a university laboratory.
Statistical analysis
Data will be analyzed on an intention-to-treat basis at the
12-week (post-testing) timepoint. The primary outcome
measure is binary - using or not using glucose-lowering
medication at 12 weeks - and data will be analyzed by lo-
gistic regression, with the stratified allocation factors in-
cluded as fixed effects together with trial arm and sex. We
will derive the odds ratio for use of glucose-lowering
medication, and odds will be converted to predicted prob-
abilities (risk differences). Participants who fail to
complete the intervention or are lost to follow up from
the Pharm-TCR group will be retained in the analyses and
will be considered as not achieving the primary outcome.
The secondary outcome measures of anthropometrics,
blood pressure, medication dose changes, quality of life,
and all blood measures will be analyzed using constrained
baseline longitudinal data analysis via a linear mixed
model [25]. This approach provides a principled method
for addressing missing data, including missing baseline
data as baseline values are part of the response vector in
this model. In addition, study site will be included as a
random effect in the linear mixed models to account for
site variability in the outcome measures [26]. Model speci-
fication will be examined by visual inspection of residuals
plots, with appropriate data transformations used if indi-
cated. For the primary endpoint we shall report the odds
ratios and predicted probabilities (risk differences) with
95% confidence intervals. Secondary continuous outcomes
will be reported as mean differences with 95% confidence
intervals. Whenever possible, data analysis will be per-
formed blinded to the allocations.
It is not anticipated that any participants in the TAU
group will discontinue glucose-lowering medications;
however, to be conservative, the sample size was calcu-
lated based on an expected proportion of medication use
of 80% in the TAU group and a 20% difference in the
proportion of participants on glucose-lowering medica-
tions at 12 weeks in the Pharm-TCR group. A sample
size of 100 per group provides 80% power to detect a
20% difference in the proportion of patients on glucose-
lowering medications, accounting for 20% attrition with
a two-sided P value of 0.05 (PASS 14 Power Analysis
and Sample Size Software, 2015. NCSS, LLC. Kaysville,
Utah, USA; ncss.com/software/pass).
Discussion
The International Diabetes Federation (IDF) estimates
the total healthcare expenditure for people with diabetes
mellitus to be ~ US$747 billion in 2017, a burden that is
expected to grow by at least 7% by the year 2045. A sub-
stantial portion of these healthcare costs are attributed
to the cost of diabetes medications; in Canada, the direct
costs related to drugs for treating T2D were ~CA$84
million in 2010 [27]. Currently, the usual treatment
paradigm for a patient newly diagnosed with T2D is to
begin drug therapy with the goal of achieving acceptable
blood glucose levels [3]. This approach has been demon-
strated to lead to extremely low levels of T2D remission
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[8] and more commonly will lead to steady progression
of the disease and eventually multi-drug therapy in order
to maintain target blood glucose levels. Reversal and re-
mission of T2D has now been shown to be possible
through substantial weight loss following bariatric sur-
gery [28] or by following a calorie-restricted diet [12]. In
addition, there is evidence that very low carbohydrate di-
ets are also effective in managing and possibly reversing
the progression of T2D [14, 29]. While these studies are
encouraging, translation of these findings into the real-
world setting must be approached with considerable care
due to risk of hypoglycemia when patients with T2D
taking glucose-lowering medications adopt therapeutic
nutrition. A key principle in this study is the careful
monitoring and systematic deprescription (Additional
file 1) of medications by trained pharmacists to address
this safety concern.
In order to assess the performance of the Pharm-TCR
intervention, primary and secondary outcomes will be
compared to the standard-care treatment for patients
with T2D. Typically a person with T2D is placed on
antihyperglycemic pharmacotherapy if they are above
their individualized A1C target with additional agents
and or dose adjustments added as needed to achieve the
target A1C [30]. By using this comparison, the trial is
designed to be as realistic as possible so that the findings
can be assessed in the context of real-world T2D man-
agement and allow for greater potential to be translated
into routine health care.
A randomized controlled trial design was chosen to
protect against potential bias arising from individual
study sites such as location, socioeconomic status of the
study site area, and possible differences in pharmacy
care. Although this meant that a given study site would
have to deliver different patient management to ran-
domly allocated patients, the “hands-off” nature of the
TAU control and the limited interaction involved does
not allow the opportunity for the pharmacist to nega-
tively bias outcomes in the TAU control-group partici-
pants. Nonetheless, the Pharm-TCR intervention is
more intense and participants necessarily receive more
attention in the chosen RCT design comparing the inter-
vention to TAU as opposed to an alternate dietary inter-
vention or weekly counseling control group.
A key principle behind this study is the emphasis on safe
deprescription of medications during the intervention
period with a focus on controlled glycemia. Furthermore,
the aim is to achieve this by using an underutilized aspect
of a care network for patients with T2D, the pharmacist,
who is well-positioned and educated for such a task.
While the implementation of a diet intervention by phar-
macists is not a conventional strategy, we utilized a stan-
dardized, commercial weight-loss diet program such that
pharmacists did not need to be experts in nutrition. This
allows pharmacists to use their unique position of fre-
quent patient interaction and extensive knowledge of
medications to safely and successfully administer the
intervention and treatment plan. Timely medication ad-
justments are essential, as blood glucose levels can be re-
duced even in the absence of weight loss when following
low-carbohydrate diets [20]. In addition, all medication
adjustments must be approved by the participants’ physi-
cians, which provides another layer of safety to the depre-
scription procedure and leverages established methods of
communication in place for pharmacists and physicians in
Canada. For these reasons, pharmacists are an innovative,
yet natural, choice to safely and effectively implement
such an intervention.
The choice for the primary outcome to be a dichotom-
ous measure of glucose-lowering medication use was
made in an effort to select a clinically relevant outcome.
Participants that are recruited for this study are expected
to have wide variability in prescribed types and doses of
glucose-lowering medications. Therefore, determining a
clinically meaningful dose reduction that would apply to
all possible medication scenarios is not feasible. How-
ever, if a T2D treatment is able to eliminate the need for
glucose-lowering medications entirely, in the absence of
significant worsening in glycemia, there is no doubt it
can be considered clinically relevant. The secondary out-
comes of A1C and fasting glucose will test whether the
very low carbohydrate and calorie-restricted dietary ap-
proach can benefit glucose control, and secondary an-
thropometric outcomes (weight, waist circumference,
and body fat percentage) will also support the primary
outcome, as substantial weight loss in patients with T2D
is associated with T2D remission [12]. With careful
documentation of glucose-lowering medication use and
measures of glucose control, it will also be possible to
report on exploratory outcomes of short-term T2D “re-
versal” using various definitions that have been
suggested in the literature, including (1) no glucose-
lowering medications, A1C below diabetes mellitus
threshold; (2) no glucose-lowering medications, A1C
and fasting glucose below diabetes mellitus thresholds;
(3) no glucose-lowering medications, A1C and/or fasting
glucose in the true normoglycemic range; and (4) A1C
below diabetes mellitus threshold and taking only met-
formin [14, 31]. Though sex will be included as a fixed
effect in the logistic regression and linear mixed ef-
fects models, a limitation of this study is the inability
to determine gender differences in the effectiveness of
the intervention. Finally, while a novel aspect of this
study is combination of the independently successful
strategies of calorie-restriction and low-carbohydrate
approach to treating T2D, a limitation of this design
is the inability to separate the effects of the two
strategies.
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Conclusion
This study will provide evidence to inform and aid in future
T2D management using pharmacist-led therapeutic carbohy-
drate restriction. It provides insight into implementing diet-
ary strategies that are increasingly being recognized as
beneficial for people with T2D with a focus on safe and effi-
cient implementation into care models. The protocol is opti-
mized to deploy pharmacists, who are well-educated in
medication management and ideally positioned to carry out
this T2D treatment strategy in the community. This
trial will determine if community pharmacists can de-
liver a very low-carbohydrate, calorie-restricted diet to
eliminate the need for glucose-lowering medication
without causing an increase in A1C.
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